Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Hønefoss – page 4

606 clinical trials in Hønefoss, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Hønefoss at a glance
606
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

606 trials in Hønefoss

Open in trial search

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Evaluation of Hydrocortisone, Octreotide, and Teres Ligament Patch Combination to Prevent Complications After Pancreatoduodenectomy in Patients with Pancreatic Head Cancer or IPMN

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Amsterdam UMC Stichting

Study on the Safety and Effects of Lutetium Lu-177 and ABY-271 in Patients with HER2-Positive Metastatic Breast Cancer

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:ABY-271
  • Sponsor:Affibody AB

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

AUC‑targeted tacrolimus dosing in kidney transplant recipients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Oslo University Hospital HF

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Hønefoss

What the registry says about research in the country

01 Musculoskeletal Diseases

In Hønefoss, researchers are evaluating non‑pharmacologic and medication approaches for acute neck pain. The study compares chiropractic spinal manipulative therapy with standard use of NSAIDs to determine which method best reduces pain intensity during the treatment period.

  • Comparative effectiveness of manual therapy versus medication
  • Measurement of pain intensity and functional recovery
  • Patient‑reported outcome measures
  • Safety and feasibility of combined treatment strategies

Findings aim to guide clinicians in selecting optimal first‑line interventions for neck pain, potentially improving recovery speed and patient satisfaction.

02 Bacterial Infections and Mycoses

Clinical investigators are studying patients with suspected community‑acquired sepsis to assess whether a regimen of narrow spectrum β‑lactam antibiotics together with an aminoglycoside is safe and non‑inferior to standard broad spectrum antibiotics. The goal is to refine early treatment choices while minimizing unnecessary broad‑spectrum exposure.

  • Early antibiotic stewardship in severe infections
  • Safety profiling of combination therapy
  • Efficacy comparison with broad‑spectrum regimens
  • Impact on patient outcomes and hospital stay

Results could support more targeted antibiotic use, preserving effectiveness of broad‑spectrum agents and reducing resistance development.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.